Rhythm Pharmaceuticals develops and sells IMCIVREE, a treatment for rare genetic forms of obesity. RYTM reports earnings on Tue, Nov 3, 2026. Analyst consensus is Strong Buy, based on the latest ratings from 7 firms (6 buy, 1 hold, 0 sell). In the past 30 days there were 1 dark pool print.
Prices, price targets and earnings estimates for RYTM are shown to AI Starter and AI Pro members. Ratings, flow and news are open to everyone.See plansSign in
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether RYTM is in one of them and how their past RYTM trades turned out.
Rhythm Pharmaceuticals is a biopharmaceutical company based in Boston, Massachusetts, in the United States. It sells IMCIVREE, a treatment that acts on the MC4R pathway in the brain, for patients with certain rare genetic forms of obesity, such as Bardet Biedl syndrome. The company is also developing other MC4R agonist treatments for hypothalamic obesity and other rare conditions. Its customers are patients with these rare diseases, along with the physicians and healthcare providers who treat them.
